Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/Italian study

被引:2
作者
Giladi, Odil [1 ,2 ]
Bagnato, Gianmarco [3 ,4 ]
Gentilini, Marianna [3 ,4 ]
Shimony, Shai [1 ,2 ,5 ]
Pasvolsky, Oren [1 ,2 ,6 ]
Berger, Tamar [1 ,2 ,7 ]
Itchaki, Gilad [1 ,2 ,8 ]
Raanani, Pia [1 ,2 ]
Lolli, Ginerva [3 ,4 ]
Stefoni, Vittorio [3 ,4 ]
Broccoli, Alessandro [3 ,4 ]
Argnani, Lisa [4 ]
Zinzani, Pier Luigi [3 ,4 ]
Gurion, Ronit [1 ,2 ]
机构
[1] Rabin Med Ctr, Davidoff Canc Ctr, Beilinson Hosp, Inst Hematol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Univ Bologna, IRCCS Azienda Osped, Ist Ematol Seragnoli, Bologna, Italy
[4] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimental, Bologna, Italy
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA
[7] Rockefeller Univ, Lab Genome Maintenance, New York, NY USA
[8] Meir Med Ctr, Hematol Inst, Kefar Sava, Israel
关键词
DLBCL (diffuse large B cell Lymphoma); COVID-19; First line treatment; Cancer care; CANCER CARE; IMPACT;
D O I
10.1007/s00277-023-05543-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The COVID-19 pandemic posed a major challenge in cancer care worldwide which might have an impact on the management of diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective study comparing characteristics, management, and outcomes of DLBCL patients diagnosed during the first year of the COVID-19 pandemic (1/3/2020-28/2/2021) to those diagnosed in the previous year (1/3/2019-28/2/2020) in two tertiary centers in Italy and Israel. 182 patients were diagnosed with DLBCL during the study period. More patients were diagnosed during the pandemic compared to the year before: 60 vs. 29 and 54 vs. 39 in Italy and in Israel, respectively. Trends towards older age and higher transformation rates were shown during the pandemic. The interval between the initiation of symptoms and diagnosis was longer during the pandemic. Five and four patients were diagnosed with COVID-19 during treatment in Italy and in Israel, respectively. there was no difference in dose density and intensity of treatment, before and during the pandemic. The median follow-up during and before the pandemic was 15.2 and 25.5 months, respectively. Progression-free survival (PFS) was slightly shorter during the pandemic compared to the year before (64.9% vs. 70.6%; p = 0.0499). In multivariate analysis, older age and transformed disease were independently related to PFS, while diagnosis of DLBCL during the pandemic was not. Despite the challenges caused by COVID-19 pandemic, the management of DLBCL patients remained unchanged including dose density and intensity. Nevertheless, a shorter PFS during the outbreak might be attributed to differences in patients' characteristics.
引用
收藏
页码:803 / 811
页数:9
相关论文
共 25 条
[1]  
Anandaradje A, 2021, CL LYMPH MYELOM LEUK, V21, pS391
[2]  
Chernichovsky D., 2019, The Healthcare System: An Overview
[3]   Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].
Cheson, Bruce D. ;
Fisher, Richard I. ;
Barrington, Sally F. ;
Cavalli, Franco ;
Schwartz, Lawrence H. ;
Zucca, Emanuele ;
Lister, T. Andrew .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+
[4]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[5]   Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy [J].
Dulery, Remy ;
Lamure, Sylvain ;
Delord, Marc ;
Di Blasi, Roberta ;
Chauchet, Adrien ;
Hueso, Thomas ;
Rossi, Cedric ;
Drenou, Bernard ;
Deau Fischer, Benedicte ;
Soussain, Carole ;
Feugier, Pierre ;
Noel, Nicolas ;
Choquet, Sylvain ;
Bologna, Serge ;
Joly, Bertrand ;
Philippe, Laure ;
Kohn, Milena ;
Malak, Sandra ;
Fouquet, Guillemette ;
Daguindau, Etienne ;
Taoufik, Yassine ;
Lacombe, Karine ;
Cartron, Guillaume ;
Thieblemont, Catherine ;
Besson, Caroline .
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (08) :934-944
[6]  
Ferrara G, 2021, AM J CLIN PATHOL, V155, P64, DOI [10.1093/ajcp/aqaa177, 10.1093/AJCP/AQAA177]
[7]   A history of Italy's health policy from the Republic to the new century [J].
Giorgi, Chiara .
MODERN ITALY, 2023, 28 (01) :1-17
[8]  
Gutierrez A., 2013, BLOOD, V122, P4374, DOI [10.1182/blood.V122.21.4374.4374, DOI 10.1182/BLOOD.V122.21.4374.4374]
[9]   Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries [J].
Islam, Nazrul ;
Shkolnikov, Vladimir M. ;
Acosta, Rolando J. ;
Klimkin, Ilya ;
Kawachi, Ichiro ;
Irizarry, Rafael A. ;
Alicandro, Gianfranco ;
Khunti, Kamlesh ;
Yates, Tom ;
Jdanov, Dmitri A. ;
White, Martin ;
Lewington, Sarah ;
Lacey, Ben .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
[10]   Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study [J].
Jazieh, Abdul Rahman ;
Akbulut, Hakan ;
Curigliano, Giuseppe ;
Rogado, Alvaro ;
Alsharm, Abdullah Ali ;
Razis, Evangelia D. ;
Mula-Hussain, Layth ;
Errihani, Hassan ;
Khattak, Adnan ;
De Guzman, Roselle B. ;
Mathias, Clarissa ;
Alkaiyat, Mohammad Omar Farouq ;
Jradi, Hoda ;
Rolfo, Christian .
JCO GLOBAL ONCOLOGY, 2020, 6 :1428-1438